The Characteristics of COVID-19 Symptoms and Skin Manifestations among Nonhospitalized COVID-19 Patients with Psoriasis during the Omicron Pandemic in China: A Single-Center Survey-Based Study
Table 2
COVID-19-related outcomes.
Variables
Total (n = 240)
BIO (n = 138)
NBT (n = 52)
TT (n = 50)
value
Hospitalization
Hospitalized
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
—
COVID-19 symptoms†, n=186
With one or more COVID-19 symptoms
186 (77.50)
113 (81.88)
39 (75.00)
34 (68.00)
0.12
The prevalence of each symptom
Fever
141 (75.81)
83 (73.45)
32 (82.05)
26 (76.47)
0.55
Cough
124 (66.67)
70 (61.95)
29 (74.36)
25 (73.53)
0.24
Fatigue
103 (55.37)
64 (56.64)
21 (53.85)
18 (52.94)
0.91
Sore muscle
94 (50.54)
57 (50.44)
20 (51.28)
17 (50.00)
0.99
Expectoration
79 (42.47)
46 (40.71)
16 (41.03)
17 (50.00)
0.62
Chilly
77 (41.40)
43 (38.05)
21 (53.85)
13 (38.24)
0.21
Back pain
67 (36.02)
44 (38.94)
11 (28.21)
12 (35.29)
0.48
Anosmia/Ageusia
64 (34.41)
39 (34.51)
17 (43.59)
8 (23.53)
0.20
Headache
63 (33.87)
39 (34.51)
12 (30.77)
12 (35.29)
0.90
Sore throat
59 (31.72)
32 (28.32)
12 (30.77)
15 (44.12)
0.22
Stuffiness
58 (31.18)
29 (25.66)
14 (35.90)
15 (44.12)
0.097
Dizzy
40 (21.51)
27 (23.89)
6 (15.38)
7 (20.59)
0.53
Joint pain
35 (18.82)
22 (19.47)
9 (23.08)
4 (11.76)
0.45
Gastrointestinal disorder
24 (12.90)
13 (11.50)
5 (12.82)
6 (17.65)
0.64
Shortness of breath (dyspnea)
24 (12.90)
13 (11.50)
8 (20.51)
3 (8.82)
0.26
Nausea
13 (6.99)
8 (7.08)
2 (5.13)
3 (8.82)
0.47
Chest pain
8 (4.30)
6 (5.31)
1 (2.56)
1 (2.94)
0.43
Duration of COVID-19 symptoms
≤7 d
138 (74.19)
84 (74.34)
28 (71.80)
26 (76.47)
0.90
>7 d
48 (25.81)
29 (25.66)
11 (28.20)
8 (23.53)
Skin manifestations after infection
No aggravation
157 (65.42)
100 (72.46)
28 (53.85)
29 (58.00)
0.026
With skin manifestation (s)
83 (34.58)
38 (27.54)
24 (46.15)
21 (42.00)
New plaque/guttate lesions
60 (25.00)
29 (21.01)
18 (34.62)
13 (26.00)
0.15
Itching
33 (13.75)
10 (7.25)
11 (21.15)
12 (24.00)
0.003
Scaly
29 (12.08)
8 (5.80)
8 (15.38)
13 (26.00)
<0.001
Continuous variables are performed as the mean (SD) and categorical variables, as count (%). Accurate statistics are chosen for the data, including one-way analysis of variance (ANOVA), Kruskal–Wallis test, and Pearson’s test (or Fisher’s exact test). A P value <0.05 is considered significant and marked into bold. †Patients might have more than one symptom so that the sum of the percentages is over 1. Abbreviations: BIO: biologics, NBT: nonbiological treatment, and TT: topical treatment or without pharmacological therapy.
